Surprise! Statins against liver cancer help develop new liver cancer drugs

Figure I Statins Improve Hepatocellular Carcinoma (HCC) Several preclinical and clinical studies have shown that statin use is associated with reduced mortality from a variety of cancers, including hepatocellular carcinoma (HCC).
For viral-related hepatocellular carcinoma (HCC), a study involving 328,946 HBV-infected patients (incidence of hepatocellular carcinoma was 310.4/100,000) showed a negative correlation between the incidence of hepatocellular carcinoma (HCC) and the use of statins.
, a wide-ranging study of HCV infections showed that a decrease in the risk of hepatocellular carcinoma (HCC) was closely related to the use of statins.
these studies have shown that statin use can help improve HBV and HCV-related hepatocellular carcinoma (HCC).
II statins improve the potential mechanisms of hepatocellular carcinoma (HCC) As shown in Figure II, Simvastatin exhibits dose-dependent inhibition on both human hepatoblastoma cells (Huh6) and HepG2 cells.
In addition to inhibiting tumor cell flux, statins have been found to improve the potential mechanisms of hepatocellular carcinoma (HCC), tumor cell apoptosis, angiogenesis, tumor cell invasion, inflammation, liver fibrosis, and HCV pathogenis.
Figure III statins affect cancer mechanisms Specifically, as shown in Figure III, there are now indications that cerivastatin, lovastatin, and simvastatin inhibit tumor proliferation.
, cerivastatin blocks the proliferation of Ras and Rho-mediated cells; lovastatin inhibits the activation of protease pathways, which leads to p21 and p27 stabilization; and Lovastatin Lovastatin blocks G1/S and G2/M conversions, blocking cell cycles, and simvastatin and lovastatin combined to inhibit hepatocellular proliferation and collagen steady state levels.
second, fluvastatin, simvastatin, and lovastatin, among the statins that induce apoptosis, reduce the MVA pathway and isoprene modifications that inhibit small G proteins; simvastatin activates the JNK path through downstream superoxidation mediating to make non-classical adjustments to RhoA and Rac1 GTPases; and Simvastatin activates Bax and lowers BCL-2; lovastatin activates caspase; and inhibits BCL-2 and ups and down Bax (by adjusting MEK-ERK path; atovastatin activates caspase-9 and caspase-3 in liver astrology cells; fluvastatin In association with celecoxib, the cell cycle protein-dependent kinase inhibitor p21 (Waf1/Cip1) was used to lower the pAkt, myeloid leukemia 1 (Mcl1) and survivin proteins.
addition, statins that affect angiogenesis and tumor cell invasion are: cerivastatin, atovastatin and simvastatin; The CV course is called lovastatin; the simvastatin, which inhibits the proliferation of embryonic stem cells; and the atorvastatin, which inhibits myc phosphorylation and activation.
, we can see that statins help improve liver cancer that has been proven by a large number of clinical and scientific trials.
, based on statins, new liver cancer drugs can be developed through new, joint and structural modification of old drugs.
can be confident that statins will continue to surprise us.
: The illustration of the article is from Reference 1 Reference: 1. Hepatocellular Carcinoma and Statins,2020; 2. Systematic review with network meta-analysis: statins and risk of hepatocellular carcinoma,2016; 3. The immunology of hepatocellular carcinoma,2018.